Terug

Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

  • Publicatie datum 11 aug 2009 - 07:32
  • Statutaire naam Crucell N.V.
  • Titel Crucell Announces Second Quarter 2009 Results
  • Bericht Total revenues and other operating income of €78.7 million, an increase of 32% compared to Q2 2008. Gross margin 39%, up from 36% in Q2 2008. Operating profit of €3.2 million versus operating loss of €9.01 million in Q2 2008. 2009 full year guidance reiterated: total revenues and other operating income expected to grow 20% in constant currencies2; operating profit for 2009 expected to improve significantly compared to 2008; solid cash flow. Leiden, the Netherlands (August 11, 2009) – Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced its financial results for the second quarter of 2009, based on International Financial Reporting Standards (IFRS). These financial results are unaudited.

Gerelateerde downloads

200908110000000004_2009 - 0811 Crucell Announces Second Quarter 2009 Results.pdf

Datum laatste update: 05 december 2021

Informatie delen

Delen via: deel